ArticleBMJ paediatrics open2025
Cost analysis of probiotic/synbiotic supplementation in infants in rural Kenya: a study from the PROSYNK trial.
Article in BMJ paediatrics open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pro/synbiotics reduce systemic inflammation and improve gut health in Kenyan infants: An open label, randomized, 4-arm, phase II trial.Cell reports. Medicine · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUndernutrition significantly contributes to infant mortality and underlies approximately 45% of global deaths in children under 5, making it one of the most concerning global child health issues. The PRObiotics and SYNbiotics in infants in Kenya (PROSYNK) trial is assessing whether supervised pro/synbiotic doses daily for the first 10 days and then weekly to age 6 months has a positive impact on gut health and thereby growth and nutrition. This study provides a cost analysis of the PROSYNK trial, estimates the costs of implementing the intervention, and offers feasability insights for delivering it to infants 0-5 months in rural Kenya.
methodsThis provider perspective costing study used a combination of the ingredients approach, activity-based costing and microcosting. First, an empirical cost analysis of the PROSYNK trial was conducted by review of trial documentation and time and motion observations. Next, semistructured interviews with key informants informed a thematic analysis of implementation feasibility and the development of a theoretical programme structure, which formed the basis for estimating total economic programme costs.
resultsThe economic cost of delivering the full pro/synbiotics course under trial conditions was measured as US$701.61 per participant. Experience gained during PROSYNK and discussions with key informants suggest that it could be feasible for the Ministry of Health (MoH) to implement programmatic delivery of the pro/synbiotics, particularly through community-based delivery, without a cold chain and with pro/synbiotic administered directly into infants' mouths. Incremental economic costs to the MoH of delivering the pro/synbiotic programmatically were estimated to be US$9.14 per infant per full course under the baseline scenario.
conclusionPro/synbiotic administration in early life may be feasible and bear similar costs to existing nutrition interventions. This study will provide policy makers and stakeholders with cost and feasibility insights to inform effective programmatic implementation in Kenya and similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.